Transcription factors point to potential drug target for autoimmune disease

h.i.v. infected t cell
HIV-infected T cell

In a step toward developing drugs against autoimmune disease, George Washington University researchers have identified proteins called transcription factors as a “vital component” in determining the function of immune T cells.

GWU’s Weiqun Peng, an associate professor of physics, and PhD candidate Zhouhao Zeng collaborated with University of Iowa immunologists to determine what gives rise to different types of T cells. Healthy people have CD4, or helper T cells, and CD8, or killer T cells, in a certain range of ratios, but people with autoimmune disease or viral infections have them in skewed proportions.

“If something goes wrong in the CD4/CD8 mix, our ability to fight off infections and diseases is compromised,” Zeng said, as reported by GW Today.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Transcription factors affect a cell’s transcription patterns, regulating gene expression. In the case of T cells, Peng’s research shows that the transcription factors Tcf1 and Lef1 activate genes in a pattern that preserve killer T cell identity. If this transcription pattern is disrupted, the cells become more like helper T cells, GW Today reported. This previously unknown function of Tcf1 and Lef1 represents a potential drug target for autoimmune disease.

“But if biomedical scientists can develop strategies to turn on/off the T-cell differentiation pathway, we might be able to make drugs that hit the molecular target" and reinforce our immune systems,” Zeng said.

Earlier this year, St. Jude researchers discovered that the oncogene c-Myc can control asymmetric division in T cells, which causes them to divide not into two identical effector or memory T cells, but into one of each. Changing the concentration of the oncogene can influence the levels of each type of cell, which can potentially lead to improved cancer treatments.

- here's the GW Today story
- and here's the study abstract

Related Articles:
C-Myc oncogene determines function of immune cells
Cancer drugs a potential therapy for autoimmune disease
Genetic element dysregulation may exacerbate autoimmune diseases

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.